Three Seasons Wealth LLC Buys Shares of 20,324 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Key Points

• Three Seasons Wealth LLC acquired 20,324 shares of Catalyst Pharmaceuticals, valued at approximately $493,000, during the first quarter, reflecting growing institutional interest in the biopharmaceutical sector.
• Analysts have given Catalyst Pharmaceuticals a strong buy rating, with an average target price of $32.83, and a total of 79.22% of the stock owned by institutional investors.
• Insider selling has occurred recently, with Gary Ingenito selling 44,000 shares for over $1 million, representing a significant decrease in his ownership position.

Three Seasons Wealth LLC purchased a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 20,324 shares of the biopharmaceutical company's stock, valued at approximately $493,000.

A number of other large investors have also recently made changes to their positions in the stock. Park Square Financial Group LLC purchased a new stake in Catalyst Pharmaceuticals during the fourth quarter valued at $29,000. Sound Income Strategies LLC bought a new stake in shares of Catalyst Pharmaceuticals during the 1st quarter valued at about $64,000. GAMMA Investing LLC increased its position in shares of Catalyst Pharmaceuticals by 26.2% during the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after purchasing an additional 579 shares during the last quarter. Quarry LP bought a new position in shares of Catalyst Pharmaceuticals in the 4th quarter worth approximately $104,000. Finally, New Vernon Capital Holdings II LLC bought a new position in shares of Catalyst Pharmaceuticals in the 4th quarter worth approximately $122,000. 79.22% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Thursday, June 5th. Six equities research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $32.83.

Catalyst Pharmaceuticals Stock Up 2.9%

NASDAQ CPRX opened at $21.73 on Tuesday. Catalyst Pharmaceuticals, Inc. has a 52 week low of $15.34 and a 52 week high of $26.58. The company has a market capitalization of $2.65 billion, a P/E ratio of 13.84, a price-to-earnings-growth ratio of 0.86 and a beta of 0.70. The stock's 50-day moving average price is $22.57 and its 200-day moving average price is $22.84.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 44,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the sale, the insider owned 68,873 shares of the company's stock, valued at approximately $1,627,468.99. This trade represents a 38.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Preethi Sundaram sold 1,600 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total transaction of $42,272.00. Following the completion of the sale, the insider owned 41,081 shares in the company, valued at approximately $1,085,360.02. This represents a 3.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 247,924 shares of company stock valued at $5,879,369 over the last three months. 10.40% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.